Tumor-Agnostic AKT Inhibition: Is It Time to AKT?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating mutations in the AKT pathway are implicated in various cancers.
• Pan-AKT inhibitors have demonstrated activity in preclinical models and early clinical trials.
• Hormone receptor-positive breast cancer is a significant area of investigation for targeted therapies.

Purpose of the Study:

• To evaluate the efficacy of pan-AKT inhibitors in a basket trial setting for AKT-mutated tumors.
• To explore the potential for AKT inhibition as a tumor-agnostic therapy.
• To assess the role of emerging AKT1 E17K-specific inhibitors.

Main Methods:

• Basket trial design enrolling patients with AKT-mutated solid tumors.
• Administration of pan-AKT inhibitors.
• Evaluation of objective response rate and safety profiles.

Main Results:

• Pan-AKT inhibitors demonstrated clinical activity in hormone receptor-positive breast cancer.
• Evidence suggests potential efficacy in other tumor types, though limited by sample size.
• Emerging AKT1 E17K-specific molecules show potential for improved tolerability and efficacy.

Conclusions:

• Pan-AKT inhibitors are a viable therapeutic option for hormone receptor-positive breast cancer.
• Further investigation is warranted to establish the tumor-agnostic potential of AKT inhibition.
• Development of specific AKT1 E17K inhibitors may enhance treatment outcomes.